Ginkgo Bioworks (DNA) to Release Earnings on Tuesday

Ginkgo Bioworks (NYSE:DNA) is expected to be posting its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Ginkgo Bioworks to post earnings of ($1.80) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:30 PM ET.

Ginkgo Bioworks Stock Performance

Shares of DNA opened at $9.33 on Tuesday. The company has a market capitalization of $565.00 million, a PE ratio of -1.50 and a beta of 1.55. The company’s 50 day moving average price is $9.14 and its 200 day moving average price is $10.80. Ginkgo Bioworks has a 52 week low of $5.00 and a 52 week high of $17.58.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DNA shares. TD Cowen lowered their price target on shares of Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Wall Street Zen cut Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $10.50.

Hedge Funds Weigh In On Ginkgo Bioworks

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Ginkgo Bioworks by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,480,504 shares of the company’s stock worth $36,166,000 after acquiring an additional 99,379 shares in the last quarter. Legal & General Group Plc lifted its holdings in Ginkgo Bioworks by 7.9% in the 3rd quarter. Legal & General Group Plc now owns 1,608,923 shares of the company’s stock worth $23,458,000 after purchasing an additional 118,402 shares during the last quarter. Millennium Management LLC boosted its position in Ginkgo Bioworks by 113.1% during the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock worth $8,137,000 after purchasing an additional 757,535 shares during the period. State Street Corp grew its holdings in Ginkgo Bioworks by 38.4% during the fourth quarter. State Street Corp now owns 1,292,071 shares of the company’s stock valued at $10,737,000 after purchasing an additional 358,231 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Ginkgo Bioworks by 23.7% in the fourth quarter. Geode Capital Management LLC now owns 999,600 shares of the company’s stock valued at $8,309,000 after purchasing an additional 191,240 shares during the period. 78.63% of the stock is currently owned by institutional investors.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.